The Neurontin accusations emerge at a time when more and more drugmakers have
come under scrutiny for their handling of research data. …
One of the big questions posed by the development of new genetic tests is how
people will react when they learn more about their risk of disease. …
The USDA ignored recommendations for a ban on the outdoor production of pharma
food crops from the Grocery Manufacturers Association, major food companies,
UCS, and more than 100 environmental, agricultural, health, and consumer
organizations. …
In the largest individual gift Harvard University has ever received, billionaire
alumni Hansjörg Wyss has donated $125 million for the establishment of a
biological engineering institute. …
Prominent physician groups, including the American Academy of Pediatricians, say
the research is weak on the drugs and that, considering the risks and the dearth
of safety and efficacy information, there isn’t a solid reason to use the
medications in children under the age of six. …
This $62 million settlement is dwarfed in comparison with previous Zyprexa
deals, including a $1 billion resolution of several thousand patient-safety
claims. …
The idea that a book can positively influence weight loss and decrease BMI is
“encouraging because it’s fairly easy to implement,” she added. “And it’s a
welcome addition to a world where there aren’t a lot of alternatives.” …
The plot is even thicker when you start looking at the FDA’s method for awarding
the PR contract. …
This year’s Nobel Prize awards discoveries of two viruses causing severe human
diseases. …
“After questioning about 20 doctors and research institutions, it looks like
problems with transparency are everywhere,” Grassley told the New York
Times. “The current system for tracking financial relationships isn’t
working.” …